# Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases

> **NCT02230306** · PHASE2 · TERMINATED · sponsor: **Melissa Burgess, MD** · enrollment: 5 (actual)

## Conditions studied

- Active Melanoma Brain Metastases

## Interventions

- **DRUG:** Cobimetinib
- **DRUG:** Vemurafenib

## Key facts

- **NCT ID:** NCT02230306
- **Lead sponsor:** Melissa Burgess, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-02
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** closed due to slow accrual
- **Last updated:** 2017-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02230306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02230306, "Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02230306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*